Lorenzini Apparels Ltd Share Price Today

Tejaswi

22 Oct • 10:11 AM · SEBI-Registered Analyst

Vijaya Diagnostic: Net Profit Rises 37.6%

VIJAYA

Vijaya Diagnostic Centre (NSE : VIJAYA) is a Hyderabad-based integrated pathology and radiology company. It runs a hub-and-spoke network of owned diagnostic centres with a direct-to-consumer model, earning EBITDA margins well above the listed diagnostics sector average. What happened: In Q1FY27, revenue grew 22.8% year on year to Rs 231 crore and net profit rose 37.6% to Rs 53.1 crore. EBITDA margin expanded 360 basis points to 42.7%. Patient footfalls grew 12.7% to 1.24 million but revenue grew faster, as tests per footfall rose to 3.7 from 3.58 and average revenue per footfall increased 9% to Rs 1,860. In FY26, revenue was Rs 814.2 crore, up 19.5%, and net profit was Rs 173 crore, up 20.3%. The company is debt-free. Why it matters: Vijaya’s 42.7% EBITDA margin in Q1FY27 compares with Dr Lal PathLabs at 31%, nearly 12 percentage points lower. ROCE stood at 25% in FY26. Revenue at 22.8% outpacing footfalls at 12.7% shows each patient visit generates more value. The company is expanding across Bengaluru, Kolkata and Pune with a capex budget of Rs 190 to 195 crore. What I am watching: 67% of revenue comes from Hyderabad. New centres in Bengaluru, Kolkata and Pune must build patient volumes quickly enough to absorb their fixed costs and match the margins of the Hyderabad business. The stock trades at a P/E of 76.2, above its five-year median of 64.8. Any margin dilution from expansion will test that premium. My stance: The operating model is among the strongest in Indian diagnostics. Zero debt, a 42.7% EBITDA margin and 37.6% profit growth are all real. Expansion beyond Hyderabad is the right move but also the key risk to margins at a P/E of 76.2. I do not hold a position in Vijaya Diagnostic at the time of writing. This is not investment advice.

THREETREND RESEARCH

19 Oct • 5:36 AM · SEBI-Registered Analyst

Rounding Bottom Breakout Concept with funndamentals

LALPATHLAB

1. Rounding Bottom Breakout Concept: A rounding bottom is a bullish chart pattern that indicates a gradual shift from selling pressure to buying interest, forming a U-shaped structure on the chart. When the price breaks above the resistance zone formed near the top of this pattern, it signals a potential bullish breakout and the beginning of a new uptrend. A breakout supported by strong trading volume, sustained price action above resistance, and a successful retest can strengthen the bullish setup. However, traders should watch for false breakouts and use proper risk management rather than assuming that the price will continue to rise. 2. Dr. Lal PathLabs — Fundamental Analysis: Dr. Lal PathLabs is a leading Indian diagnostic healthcare company that provides pathology testing, preventive health check-ups and specialised diagnostic services. Its business benefits from increasing healthcare awareness, demand for preventive testing, chronic disease monitoring and expansion into new cities. In Q1 FY27, ended June 2026, the company reported consolidated revenue of ₹798 crore, up 19.1% year-on-year, while EBITDA increased 28.7% to approximately ₹247 crore, with a 31% margin. Net profit was ₹170 crore, and cash and cash equivalents stood at ₹1,693 crore. The company is also expanding through acquisitions, including an 80% stake in Ghana-based Sunshine Healthcare. These factors support its growth outlook, although investors should monitor competition from other diagnostic chains, pricing pressure, operating costs and valuation. Overall, the company has a promising business model, but investment decisions should consider the latest quarterly results and current share valuation.

DEEPAK PAL

18 Oct • 9:21 PM · SEBI-Registered Analyst

UPCOMING IPOs--> ***** Indian Gas Exchange &...

1. ***** IPO: ₹950 CRORE FRESH ISSUE ***** co-founded by Myntra founder Mukesh Bansal, operates a fitness and active-lifestyle platform through its app, website and physical fitness centres. Key details: Fresh issue: Up to ₹950 crore Offer for Sale (OFS): Up to 17.86 crore shares Presence: 708 fitness centres across 77 cities Paid members: More than 9.87 lakh as of March 31, 2026 2. INDIAN GAS EXCHANGE (IGX): IEX PROMOTER STAKE SALE Indian Gas Exchange is a gas-trading platform promoted by Indian Energy Exchange (IEX). Key details: Proposed issue: OFS of 1.67 crore shares Promoter: Indian Energy Exchange IEX stake: 47.28% 3. SOHAN LAL COMMODITY MANAGEMENT: AGRI-LOGISTICS OPPORTUNITY Sohan Lal Commodity Management provides technology-driven agricultural logistics and commodity-management services. Its business includes: Agricultural warehousing Commodity procurement and management Collateral management Post-harvest logistics and solutions for farmers and other stakeholders 4. ESWARI GLOBAL METAL INDUSTRIES: ₹500 CRORE FRESH ISSUE Tamil Nadu-based Eswari Global Metal Industries operates in recycling and manufacturing value-added non-ferrous metal products. Key details: Fresh issue: ₹500 crore OFS: 1.32 crore shares by existing shareholders, including promoters Disclaimer: For educational and informational purposes only. This post is not investment advice. SEBI observations do not guarantee listing dates or investment returns.

Shree Dhanraksha Securities

16 Oct • 11:26 PM · SEBI-Registered Analyst

Healthcare Diagnostics Sector : Dr. Lal PathLabs

Acquisitions and Business Expansion

LALPATHLAB

is in focus after its subsidiary, PathLabs Unifiers, acquired the remaining 30% equity stake in Centrapath Labs. Acquisitions can help diagnostic companies expand their geographic presence, strengthen laboratory networks and improve service coverage. Investors should examine the purchase consideration, expected synergies, integration costs, acquired business performance and whether the transaction improves earnings per share over time. The healthcare diagnostics sector also depends on test volumes, pricing, customer retention and operational efficiency. Learning point: An acquisition creates value only when its strategic and financial benefits justify the purchase cost and integration risks.

DEEPAK PAL

14 Oct • 11:55 AM · SEBI-Registered Analyst

SECTOR CORNER---> KNOW WHICH SECTORS ARE IN NEWS & EVENTS !

Healthcare Faces Regulatory Pressure; EV Theme Puts Auto Stocks in Focus Two sectors are attracting investors’ attention today: Healthcare, amid Supreme Court scrutiny of medicine pricing, and Automobiles, as Nomura highlights opportunities linked to rising EV adoption. IT stocks are also in focus following the recent earnings-led rally. 1. HEALTHCARE & HOSPITALS: REGULATORY UNCERTAINTY RISES Morgan Stanley’s View on Indian Healthcare The Supreme Court has questioned why medicine price controls are limited to cancer drugs and why manufacturers can set prices for several other medicines and medical products. --->Stocks to Watch

APOLLOHOSP

Max Healthcare Fortis Healthcare Aster DM Healthcare Dr. Lal PathLabs Market impact: Hospital stocks may remain sensitive to developments around medicine pricing, particularly if investors expect tighter controls on pharmacy-related margins. Pharmaceutical companies could also face uncertainty if price regulation expands beyond oncology. 2. AUTOMOBILES & EVs: NOMURA FAVOURS EV-EXPOSED COMPANIES Nomura’s Preferred Auto Picks Nomura believes companies with competitive electric-vehicle products, established technology and greater EV exposure could outperform the broader automobile industry in the second half of FY27 and FY28. --->Stock View Ather Energy BUY Mahindra & Mahindra BUY Hyundai Motor India BUY Tata Motors Passenger Vehicles NEUTRAL Sona BLW Precision Forgings BUY Exide Industries BUY 3. INFORMATION TECHNOLOGY: EARNINGS-LED MOMENTUM CONTINUES Tata Elxsi also attracted attention after reporting a year-on-year increase in September-quarter profit. However, Morgan Stanley and Motilal Oswal maintained cautious views on the stock, highlighting the importance of looking beyond the immediate earnings reaction. Stocks to Watch HCLTech Tata Elxsi Tech Mahindra TCS Wipro

Ankush

13 Oct • 9:55 AM · SEBI-Registered Analyst

EXPERTS INDICATE BULLISH ON Lal PathLabs Ltd.

LALPATHLAB

Axis Direct has maintained a bullish stance on Dr Lal PathLabs, Vijaya Diagnostic Centre and Nephrocare Health Services, assigning ‘Buy’ ratings to all three stocks. The brokerage’s target prices indicate potential upside of up to 21%, supported by structural growth opportunities in India’s healthcare and diagnostics sector. For Vijaya Diagnostic Centre, Axis Direct has set a target price of Rs 1,730, indicating an upside of around 20% from the current market price of Rs 1,437. The company operates more than 140 centres across South India, offering pathology testing and advanced radiology services, including MRI, CT and PET-CT scans. The brokerage highlighted the company’s strong customer retention and healthy EBITDA margins of approximately 39%-40% as key strengths. For Nephrocare Health Services, which operates under the NephroPlus brand, Axis Direct has assigned a target price of Rs 750, implying an upside of around 21% from the current market price of Rs 616. The company is India’s and Asia’s largest specialised dialysis service provider, with 490 clinics across 269 cities in India, the Philippines, Uzbekistan and Nepal. Its network comprises 255 captive hospital clinics, 176 public-private partnership (PPP) clinics and 59 standalone centres. The brokerage also highlighted improving cash generation and capital efficiency across the organised healthcare and diagnostics sector. Operating cash flow as a proportion of EBITDA has reached 70%-80% or higher, while return on capital employed continues to improve. Combined with minimal net leverage, these factors are strengthening the financial profiles of healthcare and diagnostic companies and supporting their valuations.

Lorenzini Apparels Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Lorenzini Apparels Ltd. 👋

Expert Opinions

Frequently Asked Questions

What is the share price of Lorenzini Apparels Ltd.?

What is the market cap of Lorenzini Apparels Ltd.?

Should I buy Lorenzini Apparels Ltd. stock now?

What is the 52 week high and low of Lorenzini Apparels Ltd.?

Is the Lorenzini Apparels Ltd. stock good to buy?

Is Lorenzini Apparels Ltd. a good buy for the long term?

Is Lorenzini Apparels Ltd. overvalued or undervalued?

What is the PE and PB ratio of Lorenzini Apparels Ltd.?